Counterpoint: should systemic lytic therapy be used for submassive pulmonary embolism? No

Chest. 2013 Feb 1;143(2):299-302. doi: 10.1378/chest.12-2449.

Authors

Kathryn L Bilello¹, Susan Murin²

Affiliations

¹ Department of Medicine, University of California San Francisco-Fresno Program, Fresno, CA.
² Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, University of California, Davis, School of Medicine, Sacramento, CA; Veterans Affairs Northern California Health Care System, Sacramento, CA. Electronic address: susan.murin@ucdmc.ucdavis.edu.

PMID: 23381310
DOI: 10.1378/chest.12-2449

No abstract available

Publication types

Editorial

MeSH terms

Contraindications
Fibrinolytic Agents* / adverse effects
Hemorrhage / epidemiology
Hemorrhage / mortality
Humans
Practice Guidelines as Topic
Pulmonary Embolism / complications
Pulmonary Embolism / drug therapy*
Pulmonary Embolism / mortality
Risk Factors
Survival Rate
Thrombolytic Therapy / trends*
Ventricular Dysfunction, Right / etiology
Ventricular Dysfunction, Right / prevention & control

Substances

Fibrinolytic Agents